
Branches
Farrer Park
Mount Alvernia
Mount Alvernia – Surgical Oncology
Novena II
Orchard
Gleneagles
Icon Haematology Centre Mount Elizabeth
Mount Elizabeth
Novena I
Ongoing trials at ICON Cancer Centre
8 trials shown
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low
- Study number:
- NCT05425940
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers li
- Study number:
- NCT05338970
- Cohorts:
- 2
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants w
- Study number:
- NCT05337137
- Cohorts:
- 1
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
- Study number:
- NCT05002127
- Cohorts:
- 1
- Study phase:
- 2, 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy, Chemotherapy
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC wi
- Study number:
- NCT04685135
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Chemotherapy, Biomarker
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-lin
- Study number:
- NCT04793958
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker

Astrazeneca
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor
- Study number:
- NCT04494425
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of respo
- Study number:
- NCT03888105
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy